TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
| TCRX Stock | USD 3.33 1.31 28.23% |
Slightly above 52% of Tscan Therapeutics' investor base is interested to short. The analysis of the overall investor sentiment regarding Tscan Therapeutics suggests that many traders are impartial. Tscan Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Tscan Therapeutics' earnings reports, geopolitical events, and overall market trends.
Tscan |
Patient treated with TSC-101, the first clinical cell therapy product targeting minor histocompatibility antigen HA-2 to treat leukemia and prevent relapse following hematopoietic cell transplantationWALTHAM, Mass., March 14, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, today announced that the first pat
Read at finance.yahoo.com
 |
Tscan Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Tscan Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Tscan Therapeutics Fundamental Analysis
We analyze Tscan Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tscan Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tscan Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Tscan Therapeutics is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Tscan Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tscan Therapeutics stock to make a market-neutral strategy. Peer analysis of Tscan Therapeutics could also be used in its relative valuation, which is a method of valuing Tscan Therapeutics by comparing valuation metrics with similar companies.
Peers
Tscan Therapeutics Related Equities
| INZY | Inozyme Pharma | 9.56 | ||||
| TERN | Terns Pharmaceuticals | 5.17 | ||||
| CUE | Cue Biopharma | 3.64 | ||||
| DRMA | Dermata Therapeutics | 3.01 | ||||
| PRQR | ProQR Therapeutics | 1.51 | ||||
| CGTX | Cognition Therapeutics | 0.93 | ||||
| TFFP | Tff Pharmaceuticals | 0.67 | ||||
| XFOR | X4 Pharmaceuticals | 0.45 | ||||
| ANNX | Annexon | 0.41 | ||||
| APLS | Apellis Pharmaceuticals | 1.09 | ||||
| DAWN | Day One | 1.86 | ||||
| ITOS | Iteos Therapeutics | 2.31 | ||||
| ARWR | Arrowhead Pharmaceuticals | 3.26 | ||||
| ABOS | Acumen Pharmaceuticals | 3.56 |
Additional Tools for Tscan Stock Analysis
When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.